Transcatheter Aortic Valve Replacement: A Solution for the Young, Inoperable and Regurgitant.
Transcatheter aortic valve replacement (TAVR) has become an established treatment for patients with severe aortic stenosis and high surgical risk. Ten years of technological advances in valve structure and delivery systems alongside growing operator and centre experience has opened TAVR implantation to an increasingly broad range of patients. The extension to off-label use however needs careful consideration and monitoring. Through discussion of our case involving an inoperable 24-year-old male with severe aortic regurgitation (AR), we highlight the need for an experienced and multidisciplinary team, together with early and extensive patient and family disclosure and engagement, prior to considering any off-label application of TAVR.
Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, SA, Australia. Electronic address: kamran349@gmail.com.
Kamran
K
Majeed
Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
Andrew J
AJ
Lucking
Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
Ross L
RL
Roberts-Thomson
Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
Adam J
AJ
Nelson
Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
Joseph K
JK
Montarello
Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
Stephen G
SG
Worthley
D000328:Adult; D001022:Aortic Valve Insufficiency / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D008297:Male; D065467:Transcatheter Aortic Valve Replacement / Q000379:methods*
Aortic regurgitation; Aortic stenosis; Off-label indications; Transcatheter Aortic Valve Replacement (TAVR)